This would apply equally to tumors with endogenous NIS expression such as thyroid or breast cancer, to tumors in which NIS expression may be induced, such as poorly differentiated or anaplastic thyroid cancer, and to tumors in which NIS gene therapy may be administered, such as prostate or ovarian cancer. This evidence concerns the gene SLC5A5 and breast carcinoma.